No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.7x · 10Y median 6.3x · 6th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:06:19.162Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for CVRx, Inc. (CVRX) stock was $1.62 as of Oct 6, 2026, 11:05 AM EDT, up 3.53% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -81.9% · 3-year avg -52.6%/yr · 5-year avg -37.9%/yr
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases.
Medical - Devices · Minneapolis, MN
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.49
Revenue Est.
$13.93M
Last Quarter Results
EPS
$-0.53
vs Estimate
$-0.52
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CVRX | $42.86M | $1.61 | +3.53% | -81.94% | -37.86% | N/A | N/A |
| 2FLNA | $41.71M | $0.86 | -0.74% | N/A | N/A | N/A | vs CVRX |
| 3DRIO | $44.31M | $6.06 | +4.48% | -64.35% | -52.92% | -42.38% | vs CVRX |
| 4NNOX | $44.53M | $0.64 | -0.50% | -83.50% | -51.28% | N/A | vs CVRX |
| 5BSEM | $44.84M | $2.64 | -4.17% | -44.20% | +15.72% | -12.08% | vs CVRX |
| 6HOWL | $45.17M | $0.93 | -0.06% | -54.46% | -44.27% | N/A | vs CVRX |
N/A
$15.71M
vs Estimate
$15.55M
Consensus Rating
Based on 6 analysts
Average Price Target
$4.58
+183.8% upside
Low
$3.50
Current
$1.61
High
$6.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.54 | $-0.50 | $-0.48 | 4 |
| Quarter ending Dec 2026 | $-0.50 | $-0.49 | $-0.47 | 4 |
| Quarter ending Mar 2027 | $-0.54 | $-0.51 | $-0.49 | 1 |
| Quarter ending Jun 2027 | $-0.54 | $-0.51 | $-0.49 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.06 | $-2.01 | $-1.96 | 5 |
| FY 2027 | $-2.09 | $-1.93 | $-1.77 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $13.81M | $13.93M | $14.17M | 4 |
| Quarter ending Dec 2026 | $14.19M | $14.46M | $14.98M | 4 |
| Quarter ending Mar 2027 | $14.90M | $15.27M | $15.93M | 2 |
| Quarter ending Jun 2027 | $15.83M | $16.23M | $16.93M | 2 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $58.54M | $58.96M | $59.35M | 5 |
| FY 2027 | $63.02M | $65.28M | $66.71M | 5 |
